CSCI: AI 评分 63/100 — AI 分析 (4月 2026)

COSCIENS Biopharma Inc. (CSCI) is a specialty biopharmaceutical company focused on developing and commercializing therapeutics and diagnostic tests, with a lead product, Macrilen, for growth hormone deficiency. The company operates internationally, seeking to address unmet needs in endocrinology, oncology, and neurological disorders.

Key Facts: Price: $2.72 AI Score: 63/100 Sector: Healthcare

公司概况

概要：

COSCIENS Biopharma (CSCI) pioneers innovative therapeutics and diagnostics, highlighted by Macrilen for growth hormone deficiency, targeting endocrinology and oncology markets; despite a negative P/E of -0.34, CSCI leverages strategic partnerships to expand its global footprint and address critical unmet medical needs.

CSCI是做什么的？

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics and diagnostic tests. Incorporated in 1990 and headquartered in Toronto, Canada, the company has evolved to focus on addressing unmet medical needs in endocrinology, oncology, and neurological disorders. COSCIENS's lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor agonist used for the diagnosis of adult and childhood-onset growth hormone deficiency. Macrilen stimulates growth hormone secretion, offering a valuable diagnostic tool for endocrinologists. Beyond Macrilen, COSCIENS is advancing a pipeline of preclinical assets, including AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide for chronic hypoparathyroidism, and AEZS-130 for amyotrophic lateral sclerosis. The company also has a license and research agreement with the University of Wuerzburg to develop AIM biologicals for neuromyelitis optica spectrum disorder and Parkinson's disease. COSCIENS collaborates with Consilient Health Ltd., NK MEDITECH Ltd., Er-Kim Pharmaceuticals Bulgaria Eood, and The University of Sheffield to expand the development and commercialization of its products. This strategic approach allows COSCIENS to leverage external expertise and resources to accelerate its pipeline and broaden its market reach across Canada, Switzerland, Ireland, Denmark, Germany, the United States, and other international markets.

CSCI的投资论点是什么？

COSCIENS Biopharma presents a speculative investment opportunity within the biotechnology sector, driven by its lead product, Macrilen, and a pipeline of preclinical assets. While the company currently operates with a negative P/E ratio of -0.34 and a profit margin of -153.4%, the potential for Macrilen to capture a larger share of the growth hormone deficiency diagnostics market is a key value driver. The company's gross margin of 42.1% indicates potential for profitability as revenue scales. Upcoming catalysts include the advancement of AEZS-150 and AEZS-130 through preclinical trials and potential partnership agreements for further development and commercialization. The company's collaborations with universities and other companies could provide access to innovative technologies and expand its product portfolio. Success in these areas could significantly enhance shareholder value, although the inherent risks associated with biotechnology investments must be considered.

CSCI在哪个行业运营？

COSCIENS Biopharma operates in the competitive biotechnology industry, characterized by rapid innovation and high regulatory hurdles. The market for growth hormone deficiency diagnostics and therapeutics is growing, driven by increased awareness and improved diagnostic tools. COSCIENS competes with larger pharmaceutical companies and other biotechnology firms developing treatments for endocrine and neurological disorders. The company's success depends on its ability to secure regulatory approvals, establish strategic partnerships, and effectively commercialize its products. The industry is also subject to pricing pressures and evolving reimbursement policies.

Biotechnology

Healthcare

CSCI有哪些增长机遇？

Expansion of Macrilen's Market Reach: COSCIENS can expand Macrilen's market reach by securing additional distribution agreements and regulatory approvals in new territories. The global market for growth hormone deficiency diagnostics is estimated to reach several billion dollars, offering significant potential for revenue growth. Timeline: Ongoing, with continuous efforts to penetrate new markets.
Advancement of AEZS-150 for Hypoparathyroidism: The development of AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide, represents a significant growth opportunity in the treatment of chronic hypoparathyroidism. The market for hypoparathyroidism therapies is underserved, with a growing need for more effective treatments. Timeline: Preclinical trials ongoing, with potential for clinical trials in the next 1-2 years.
Development of AEZS-130 for ALS: The preclinical development of AEZS-130 for amyotrophic lateral sclerosis (ALS) offers a high-potential growth opportunity. ALS is a devastating neurodegenerative disease with limited treatment options, creating a significant unmet medical need. Timeline: Preclinical trials ongoing, with potential for clinical trials in the next 2-3 years.
AIM Biologicals for Neuromyelitis Optica Spectrum Disorder (NMOSD): The license and research agreement with the University of Wuerzburg to develop AIM biologicals for NMOSD provides a pathway to address a rare autoimmune disease affecting the central nervous system. The NMOSD market has seen increased attention with the development of targeted therapies. Timeline: Preclinical development, with potential for clinical trials in the next 3-4 years.
Partnerships and Licensing Agreements: COSCIENS can pursue additional partnerships and licensing agreements to expand its product portfolio and geographic reach. Collaborations with other biotechnology companies and research institutions can accelerate the development and commercialization of innovative therapies. Timeline: Ongoing, with continuous efforts to identify and secure strategic partnerships.

Market Cap of $0.01B reflects its micro-cap status and potential for high growth but also higher volatility.
Gross Margin of 42.1% indicates a solid foundation for profitability as revenue increases.
Lead product Macrilen targets a significant market in growth hormone deficiency diagnostics.
Beta of 1.85 suggests higher volatility compared to the overall market.
Strategic collaborations with University of Wuerzburg and others enhance pipeline development.

CSCI提供哪些产品和服务？

Develop and commercialize therapeutics and diagnostic tests.
Focus on endocrinology, oncology, and neurological disorders.
Offer Macrilen (macimorelin) for growth hormone deficiency diagnosis.
Advance preclinical assets like AEZS-150 for hypoparathyroidism.
Develop AEZS-130 for amyotrophic lateral sclerosis.
Collaborate with universities and companies for research and development.
Seek regulatory approvals for new products and indications.

CSCI如何赚钱？

Develop pharmaceutical products through internal research and development.
License and acquire rights to promising drug candidates.
Partner with other companies for development and commercialization.
Generate revenue through product sales and licensing agreements.

Endocrinologists and other physicians.
Hospitals and clinics.
Diagnostic laboratories.
Patients with growth hormone deficiency and other endocrine disorders.

Proprietary formulations and intellectual property for Macrilen.
Strategic partnerships with leading research institutions.
Pipeline of preclinical assets targeting unmet medical needs.
Established distribution network in key markets.

什么因素可能推动CSCI股价上涨？

Upcoming: Advancement of AEZS-150 into clinical trials for hypoparathyroidism.
Upcoming: Advancement of AEZS-130 into clinical trials for ALS.
Ongoing: Expansion of Macrilen's market reach through new distribution agreements.
Ongoing: Potential for new partnerships and licensing agreements.
Ongoing: Regulatory approvals for new products and indications.

CSCI的主要风险是什么？

Potential: Dilution of existing shareholders through future equity offerings.
Ongoing: High cash burn rate and limited financial resources.
Potential: Regulatory setbacks and delays in product approvals.
Potential: Competition from larger pharmaceutical companies.
Ongoing: Product liability claims and litigation.

CSCI的核心优势是什么？

Lead product Macrilen with established market presence.
Pipeline of preclinical assets targeting unmet medical needs.
Strategic collaborations with universities and companies.
Experienced management team with expertise in drug development.

CSCI的劣势是什么？

Negative P/E ratio and profit margin.
Limited financial resources.
High reliance on Macrilen for revenue.
Dependence on regulatory approvals for product commercialization.

CSCI有哪些机遇？

Expansion of Macrilen's market reach.
Advancement of preclinical assets through clinical trials.
Acquisition of new drug candidates and technologies.
Strategic partnerships for development and commercialization.

CSCI面临哪些威胁？

Competition from larger pharmaceutical companies.
Regulatory hurdles and delays.
Pricing pressures and reimbursement challenges.
Product liability claims.

CSCI的竞争对手是谁？

Apogee Therapeutics, Inc. — Focuses on biologics for inflammatory and immunological diseases. — (APGN)
Bio-Orthopaedics, Inc. — Develops and commercializes products for the treatment of musculoskeletal diseases. — (BIOR)
Chromadex Corp — Focuses on dietary supplements and ingredients for health and wellness. — (CHRO)
Corvus Pharmaceuticals Inc — Develops and commercializes novel immuno-oncology therapies. — (CRVO)
IMV Inc — Develops immune-educating therapies for cancer and infectious diseases. — (IMVIF)

Key Metrics

Price: $2.72 (-6.91%)
Market Cap: $9.0M
Volume: 300
MoonshotScore: 63/100

常见问题

What does COSCIENS Biopharma Inc. (CSCI) do?

COSCIENS Biopharma Inc. (CSCI) is a specialty biopharmaceutical company focused on developing and commercializing therapeutics and diagnostic tests. Its lead product, Macrilen (macimorelin), is used for diagnosing growth hormone deficiency in adults and children. Additionally, COSCIENS is developing a pipeline of preclinical assets targeting conditions like hypoparathyroidism and amyotrophic lateral sclerosis, aiming to address unmet medical needs through innovative pharmaceutical solutions and strategic collaborations.

Is CSCI stock a good buy?

Evaluating whether CSCI stock is a good buy requires careful consideration. While COSCIENS has a lead product in Macrilen and a pipeline of preclinical assets, the company's negative P/E ratio of -0.34 and a profit margin of -153.4% suggest financial challenges. The potential for growth lies in the successful development and commercialization of its pipeline and expansion of Macrilen's market reach, but investors should weigh these opportunities against the inherent risks of biotechnology investments and the company's current financial position.

What are the main risks for CSCI?

Investing in COSCIENS Biopharma (CSCI) carries several risks. The company's high cash burn rate and limited financial resources raise concerns about potential dilution through future equity offerings. Regulatory setbacks and delays in product approvals could significantly impact the company's pipeline development and commercialization efforts. Additionally, competition from larger pharmaceutical companies and potential product liability claims pose ongoing threats to CSCI's financial stability and market position.

What catalysts could move CSCI stock?

Several catalysts could potentially move CSCI stock. Positive clinical trial results for AEZS-150 in hypoparathyroidism or AEZS-130 in ALS could drive investor interest. Expansion of Macrilen's market reach through new distribution agreements and regulatory approvals in additional territories could also boost revenue and stock price. Furthermore, any new partnerships or licensing agreements that expand COSCIENS's product portfolio could serve as positive catalysts.

What is CSCI stock price target?

As of March 2, 2026, there is no available analyst consensus price target for CSCI stock due to its micro-cap status and limited analyst coverage. A fair value estimate would require a detailed financial model incorporating projected revenue growth from Macrilen and its pipeline assets, discounted cash flow analysis, and consideration of the inherent risks associated with biotechnology investments. Investors should conduct their own due diligence and consider their risk tolerance before investing.